Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:SMTI NASDAQ:SRTS NASDAQ:STEX NASDAQ:TLSI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSMTISanara MedTech$23.17$19.19$16.05▼$35.95$212.33M1.1647,239 shs45,371 shsSRTSSensus Healthcare$3.19$3.93$2.82▼$5.92$52.51M1.1983,263 shs38,049 shsSTEXBiosig Technologies$1.28$1.16$0.70▼$14.11$231.86M1.581.54 million shs4.21 million shsTLSITriSalus Life Sciences$3.26$4.04$2.20▼$7.95$199.86M0.56711,760 shs393,402 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSMTISanara MedTech0.00%+10.02%+20.55%+11.82%-23.76%SRTSSensus Healthcare0.00%-11.63%-19.04%-16.49%-31.98%STEXBiosig Technologies0.00%+33.51%+25.49%-40.47%+127,999,900.00%TLSITriSalus Life Sciences0.00%+21.64%-29.74%-34.67%-41.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSMTISanara MedTech$23.17$19.19$16.05▼$35.95$212.33M1.1647,239 shs45,371 shsSRTSSensus Healthcare$3.19$3.93$2.82▼$5.92$52.51M1.1983,263 shs38,049 shsSTEXBiosig Technologies$1.28$1.16$0.70▼$14.11$231.86M1.581.54 million shs4.21 million shsTLSITriSalus Life Sciences$3.26$4.04$2.20▼$7.95$199.86M0.56711,760 shs393,402 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSMTISanara MedTech0.00%+10.02%+20.55%+11.82%-23.76%SRTSSensus Healthcare0.00%-11.63%-19.04%-16.49%-31.98%STEXBiosig Technologies0.00%+33.51%+25.49%-40.47%+127,999,900.00%TLSITriSalus Life Sciences0.00%+21.64%-29.74%-34.67%-41.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceSMTISanara MedTech 2.00Hold$34.0046.74% UpsideSRTSSensus Healthcare 2.57Moderate Buy$6.88115.52% UpsideSTEXBiosig Technologies 2.00Hold$8.00525.00% UpsideTLSITriSalus Life Sciences 2.25Hold$7.50130.06% UpsideCurrent Analyst Ratings BreakdownLatest SRTS, SMTI, TLSI, and STEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026STEXBiosig Technologies Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $8.005/13/2026TLSITriSalus Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026TLSITriSalus Life Sciences Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.005/12/2026SMTISanara MedTech Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/8/2026SRTSSensus Healthcare CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/1/2026STEXBiosig Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026SMTISanara MedTech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026SRTSSensus Healthcare Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/15/2026SMTISanara MedTech Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$32.004/10/2026TLSITriSalus Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026STEXBiosig Technologies Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $9.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookSMTISanara MedTech$103.12M2.06$0.59 per share38.97$0.77 per share30.09SRTSSensus Healthcare$27.48M1.91N/AN/A$2.77 per share1.15STEXBiosig TechnologiesN/AN/AN/AN/A$0.88 per shareN/ATLSITriSalus Life Sciences$44.88M4.45N/AN/A$0.21 per share15.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateSMTISanara MedTech-$37.56M-$3.77N/AN/AN/A-31.23%-3.19%-0.56%8/12/2026 (Estimated)SRTSSensus Healthcare-$7.72M-$0.47N/AN/AN/A-34.50%-15.79%-14.02%8/6/2026 (Estimated)STEXBiosig Technologies-$462.77M-$9.71N/AN/AN/AN/A-717.92%-336.75%N/ATLSITriSalus Life Sciences-$39.23M-$1.41N/AN/AN/A-60.85%N/A-69.91%8/11/2026 (Estimated)Latest SRTS, SMTI, TLSI, and STEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026STEXBiosig TechnologiesN/A$999.00N/A$999.00N/AN/A5/7/2026Q1 2026SRTSSensus Healthcare-$0.1250-$0.16-$0.0350-$0.16$5.32 million$3.39 million3/31/2026Q4 2025STEXBiosig TechnologiesN/A-$8.23N/A-$8.23N/AN/A3/24/2026Q4 2025SMTISanara MedTech$0.11$0.04-$0.07-$0.19$27.90 million$27.55 million3/5/2026Q4 2025TLSITriSalus Life Sciences-$0.13-$0.12+$0.01-$0.21$13.20 million$13.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthSMTISanara MedTechN/AN/AN/AN/AN/ASRTSSensus HealthcareN/AN/AN/AN/AN/ASTEXBiosig TechnologiesN/AN/AN/AN/AN/ATLSITriSalus Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioSMTISanara MedTech6.592.282.05SRTSSensus HealthcareN/A7.274.03STEXBiosig TechnologiesN/A13.9013.90TLSITriSalus Life Sciences2.585.785.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipSMTISanara MedTech8.10%SRTSSensus Healthcare25.30%STEXBiosig Technologies7.16%TLSITriSalus Life Sciences2.58%Insider OwnershipCompanyInsider OwnershipSMTISanara MedTech42.00%SRTSSensus Healthcare10.20%STEXBiosig Technologies52.73%TLSITriSalus Life Sciences16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableSMTISanara MedTech609.16 million5.32 millionNot OptionableSRTSSensus Healthcare4016.46 million14.78 millionOptionableSTEXBiosig Technologies50181.14 million85.63 millionN/ATLSITriSalus Life Sciences10661.31 million51.31 millionNot OptionableSRTS, SMTI, TLSI, and STEX HeadlinesRecent News About These CompaniesTLSI ALERT: Levi & Korsinsky Investigates TriSalus Life Sciences, Inc. on Behalf of Shareholders Who Lost MoneyMay 24 at 12:06 AM | newsfilecorp.comNTLSI (TLSI) Securities Fraud Investigation - Levi & KorsinskyMay 22 at 9:00 AM | prnewswire.comSecurities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading ...May 20, 2026 | tmcnet.comSecurities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmMay 20, 2026 | businesswire.comTriSalus Life Sciences Inc. (TLSI) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationMay 20, 2026 | businesswire.comSecurities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzMay 19, 2026 | tmcnet.comLost Money on TriSalus Life Sciences, Inc. (TLSI)? Possible Fraud - Contact Levi & Korsinsky TodayMay 19, 2026 | newsfilecorp.comNTLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities FraudMay 19, 2026 | businesswire.comSecurities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzMay 19, 2026 | businesswire.comTriSalus Life Sciences (NASDAQ:TLSI) Director Purchases $24,600.00 in StockMay 19, 2026 | insidertrades.comLost Money on TriSalus Life Sciences, Inc. (TLSI)? Contact Levi & Korsinsky to Protect Your RightsMay 14, 2026 | newsfilecorp.comNTriSalus outlines $54M-$57M 2026 revenue forecast while TriNav Advance clearance runs ~5 months past goalMay 14, 2026 | seekingalpha.comTriSalus Life Sciences Q1 Earnings Call HighlightsMay 12, 2026 | marketbeat.comTriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue EstimatesMay 12, 2026 | zacks.comEarnings To Watch: TriSalus Life Sciences Inc (TLSI) Reports Q1 2026 ResultMay 11, 2026 | finance.yahoo.comTriSalus (TLSI) Initiates Patient Enrollment for PREDICTT Liver Tumor Clinical TrialMay 10, 2026 | uk.finance.yahoo.comLake Street Remains a Buy on TriSalus Life Sciences (TLSI)May 7, 2026 | theglobeandmail.comTriSalus Life Sciences (TLSI) Projected to Post Quarterly Earnings on TuesdayMay 5, 2026 | marketbeat.comTriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver TumorsMay 4, 2026 | businesswire.comTriSalus Life Sciences Announces Planned Clinical Leadership TransitionApril 29, 2026 | tipranks.comTriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference CallApril 28, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSRTS, SMTI, TLSI, and STEX Company DescriptionsSanara MedTech NASDAQ:SMTI$23.17 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$23.40 +0.23 (+0.99%) As of 05/22/2026 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.Sensus Healthcare NASDAQ:SRTS$3.19 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.20 +0.00 (+0.16%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.Biosig Technologies NASDAQ:STEX$1.28 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.33 +0.05 (+3.83%) As of 05/22/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.TriSalus Life Sciences NASDAQ:TLSI$3.26 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.38 +0.12 (+3.65%) As of 05/22/2026 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
